Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 19;8(1):262.
doi: 10.1186/s40814-022-01224-8.

Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial

Xiao-Yang Hu  1 , Tom Oliver  2 , Merlin Willcox  3 , Catherine Simpson  2 , Kerensa Thorne  2 , Jeanne Trill  3 , Nick Francis  3 , Beth Stuart  4 , Michael Thomas  3 , Paul Little  3 , Jian-Ping Liu  5 , Gareth Griffiths  2 , Michael Moore  3
Affiliations

Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial

Xiao-Yang Hu et al. Pilot Feasibility Stud. .

Abstract

Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a major reason for consultations in primary care, hospital admissions, deterioration in function, and mortality. Despite the majority of exacerbations not being caused by bacteria, as many as 70% of patients who present in UK primary care with AECOPD are prescribed antibiotics as part of standard care. However, finding effective non-antibiotic treatments for COPD exacerbations is a priority to reduce antibiotic use. The Chinese herbal medicine Shufeng Jiedu® (SFJD) has the potential to reduce treatment failure and duration of hospital stay. This study aims to determine the feasibility of conducting a fully powered randomised, double blind, placebo-controlled clinical trial on SFJD for AECOPD in UK primary care.

Methods: This study is a phase III, two-arm individually double blind, randomised, placebo-controlled feasibility trial with nested qualitative study, coordinated by the Southampton Clinical Trial Unit (SCTU). Patients aged ≥ 40 years, with a current AECOPD, presenting with increased sputum purulence/volume, or breathlessness, and for whom the GP is considering use of antibiotics, will be eligible to participate. We aim to recruit seven eligible participants per month and randomise them to receive either the patent Chinese herbal medicine SFJD capsules or placebo for 14 consecutive days and to follow-up for 12 weeks. The primary outcomes include the feasibility of recruitment, study retention, and the percentage of diary completion.

Discussion: If this trial demonstrates the feasibility of recruitment, delivery, and follow-up, we will seek funding for a fully powered placebo-controlled trial of SFJD for the treatment of AECOPD in primary care.

Trial registration: This trial is registered via ISRCTN on 1 July 2021, identifier: ISRCTN26614726.

Keywords: Chronic obstructive pulmonary disease; Exacerbation; Feasibility; Herbal medicine; Qualitative; Randomised controlled trial.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Trial schema
Fig. 2
Fig. 2
EXCALIBUR IMP flow chart
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. GOLD. 2022 GOLD Report. 2021 [cited 2022; Available from: https://goldcopd.org/2022-gold-reports-2/.
    1. Collaborators, GCRD Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi: 10.1016/S2213-2600(20)30105-3. - DOI - PMC - PubMed
    1. NICE. Chronic obstructive pulmonary disease in adults Quality standard [QS10]. 2011; Available from: https://www.nice.org.uk/guidance/qs10/chapter/introduction.
    1. Macdonald, A.K.C.B.M. Support for people with chronic obstructive pulmonary disease. 2021 [cited 2022; Available from: https://commonslibrary.parliament.uk/research-briefings/cdp-2021-0188/.
    1. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom. 2018;3:e4. doi: 10.1017/gheg.2018.1. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources